Molecular Formula | C51H70N10O12S2 |
Molar Mass | 1079.3 |
Melting Point | 153-156°C |
Boling Point | 1447.2°C at 760 mmHg |
Specific Rotation(α) | D20 -42° (c = 0.5 in 95% acetic acid) |
Flash Point | 829.1°C |
Solubility | H2O: soluble |
Vapor Presure | 0mmHg at 25°C |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vivo study | Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated. |
WGK Germany | 3 |
HS Code | 2937190000 |
Toxicity | TDLo scu-man: 2587 mg/kg:GIT,LVR LANCAO348,1668,1996 |
Reference Show more | 1. Zhang Li, Jiang Cheng, Chen Simin, Yao Ting, Xiang Ningling, Su Mengxiang, Di bin. Determination of plasma protein binding rate of peptide candidates by dextran charcoal adsorption [J]. Journal of China Pharmaceutical University, 2020,51(05):522-529. |
is so far the only successful application in the treatment of gastrointestinal hormone analogs, is a synthetic octapeptide containing a cyclic structure, part of the amino acid sequence similar to somatostatin, with almost all the biological effects of somatostatin, such as inhibition of a variety of pituitary and gastrointestinal pancreatic hormone release, inhibition of gastric acid, pancreatic juice and bile secretion, inhibition of gastrointestinal motility and secretion, etc., but the half-life of somatostatin 30 times.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
10 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
usage and dosage for the treatment of VIP tumor, carcinoid syndrome and gastrinoma. Insulinoma and glucagonoma, 50 ~ lOOug subcutaneous injection every time, 1~2 times a day, can be maintained by intermittent medication after symptom relief. It can also be used to treat acromegaly caused by growth hormone releasing factor (GHF) tumor. In the treatment of gastrointestinal disease fistula, Diarrhea, cirrhosis of the liver and portal hypertension and esophageal variceal bleeding, gastric ulcer disease bleeding, acute pancreatitis.
side effects were Abdominal Pain, abdominal distension, Diarrhea, steatorrhea; Gallstone formation; Glucose tolerance may decrease or worsen in the early stage of treatment, and then improve; No endogenous antibody production in long-term use, there was no obvious rebound or adverse reaction when the drug was stopped and rapidly reduced. The remainder was octreotide acetate.